Houston Methodist's CAMPER Designs MRSA‑Killing Peptide
Get the Health newsletter
Daily health & science — research, biotech, public health, the studies worth knowing. Free.
- Houston Methodist researchers, led by Eleftherios Mylonakis, published a Nature Communications study describing an AI-powered platform for designing antimicrobial peptides targeting MRSA.
- CAMPER (Constraint-driven AMP Engineering with Ranking) combines machine learning with biologically informed features to evaluate and rank peptide libraries based on physical and chemical properties and predicted performance.
- Fadi Shehadeh and Biswajit Mishra, as first authors, used CAMPER to identify the peptide WP‑CAMPER1, which demonstrated potent activity against MRSA at low concentrations in laboratory tests.
- U.S. faces an estimated 2.8 million antibiotic‑resistant infections and over 35,000 deaths annually, highlighting the health threat addressed by the new peptide designs.
- Mylonakis says the CAMPER methodology represents a scalable step toward developing therapeutics for complex pathogens and persistent infections.
Why it matters: The CAMPER platform provides a scalable way to generate antimicrobial peptides, directly tackling the U.S. burden of 2.8 million antibiotic‑resistant infections. Its ability to rank and select candidates based on physical and chemical properties led to WP‑CAMPER1, which showed potent MRSA activity at low concentrations in lab tests, accelerating early‑stage therapeutic discovery.
